

# Prevalence, Correlates, Disability, and Comorbidity of DSM-IV Borderline Personality Disorder: Results From the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions

Bridget F. Grant, Ph.D., Ph.D.; S. Patricia Chou, Ph.D.;  
Risë B. Goldstein, Ph.D., M.P.H.; Boji Huang, M.D., Ph.D.;  
Frederick S. Stinson, Ph.D.; Tulshi D. Saha, Ph.D.;  
Sharon M. Smith, Ph.D.; Deborah A. Dawson, Ph.D.;  
Attila J. Pulay, M.D.; Roger P. Pickering, M.S.; and W. June Ruan, M.A.

---

**Objectives:** To present nationally representative findings on prevalence, sociodemographic correlates, disability, and comorbidity of borderline personality disorder (BPD) among men and women.

**Method:** Face-to-face interviews were conducted with 34,653 adults participating in the 2004–2005 Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Personality disorder diagnoses were made using the Wave 2 Alcohol Use Disorder and Associated Disabilities Interview Schedule–DSM-IV Version.

**Results:** Prevalence of lifetime BPD was 5.9% (99% CI = 5.4 to 6.4). There were no differences in the rates of BPD among men (5.6%, 99% CI = 5.0 to 6.2) and women (6.2%, 99% CI = 5.6 to 6.9). BPD was more prevalent among Native American men, younger and separated/divorced/widowed adults, and those with lower incomes and education and was less prevalent among Hispanic men and women and Asian women. BPD was associated with substantial mental and physical disability, especially among women. High co-occurrence rates of mood and anxiety disorders with BPD were similar. With additional comorbidity controlled for, associations with bipolar disorder and schizotypal and narcissistic personality disorders remained strong and significant (odds ratios  $\geq 4.3$ ). Associations of BPD with other specific disorders were no longer significant or were considerably weakened.

**Conclusions:** BPD is much more prevalent in the general population than previously recognized, is equally prevalent among men and women, and is associated with considerable mental and physical disability, especially among women. Unique and common factors may differentially contribute to disorder-specific comorbidity with BPD, and some of these associations appear to be sex-specific. There is a need for future epidemiologic, clinical, and genetically informed studies to identify unique and common factors that underlie disorder-specific comorbidity with BPD. Important sex differences observed in rates of BPD and associations with BPD can inform more focused, hypothesis-driven investigations of these factors.

(*J Clin Psychiatry* 2008;69:533–545)

Received Nov. 13, 2007; accepted Jan. 7, 2008. From the Laboratory of Epidemiology and Biometry, Division of Intramural Clinical and Biological Research, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Md.

This research was supported in part by the Intramural Program of the National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism (NIAAA). The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) is funded by the NIAAA with supplemental support from the National Institute on Drug Abuse (NIDA).

Dr. Grant had full access to all of the data in this study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of sponsoring organizations, agencies, or the U.S. government.

The authors report no additional financial or other relationships relevant to the subject of this article.

Corresponding author and reprints: Bridget F. Grant, Ph.D., Ph.D., Laboratory of Epidemiology and Biometry, Room 3077, Division of Intramural Clinical and Biological Research, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, M.S. 9304, 5635 Fishers Lane, Bethesda, MD 20892-9304 (e-mail: bgrant@willco.niaaa.nih.gov).

**B**orderline personality disorder (BPD) is a complex, serious psychiatric disorder characterized by pervasive instability in regulation of emotion, self-image, interpersonal relationships, and impulse control.<sup>1</sup> BPD is the most prevalent personality disorder in clinical settings and is associated with severe functional impairment, substantial treatment utilization, and high rates of mortality by suicide.<sup>2–5</sup> Clinical studies have also shown BPD to be highly comorbid with most substance use, mood, anxiety, and other personality disorders.<sup>6–12</sup>

Although BPD is among the most frequently studied personality disorders in clinical settings, little is known about its prevalence, correlates, disability, and comorbidity in general population samples. Several earlier community studies<sup>13–27</sup> of BPD were limited by selection of small samples (Ns of 133–799) not entirely representative of the general population. Others preselected individuals from larger general population samples on the basis of responses to personality disorder screening instruments or psychopathology,<sup>15,19,20,24</sup> further limiting the size of the

survey samples on which to base prevalence estimates. Of the 2 larger-scale epidemiologic surveys, the one conducted in Norway<sup>28</sup> (N = 2053) was compromised by a low response rate (57%), and the Australian survey<sup>29</sup> (N = 10,641) used a personality disorder screening measure rather than a diagnostic assessment instrument to assess personality disorders. Because of these limitations, very little is known about the sociodemographic characteristics, disability, and comorbidity of BPD with other psychiatric disorders. The 1 study that presented data on disorder-specific comorbidity<sup>19</sup> did not control for other comorbid disorders, thereby precluding analysis of common and unique factors underlying disorder-specific associations with BPD.

The lack of comprehensive and detailed information on DSM-IV BPD in the United States represents a gap in our knowledge relevant to prevention, treatment, and economic costs. The present study was designed to address this gap using data from the 2004–2005 Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).<sup>30</sup> The Wave 2 NESARC covered DSM-IV alcohol and specific drug use disorders, and mood and anxiety disorders assessed in the 2001–2002 Wave 1 NESARC,<sup>31,32</sup> in addition to BPD, schizotypal and narcissistic personality disorders, and posttraumatic stress disorder (PTSD). The remaining DSM-IV personality disorders (avoidant, dependent, obsessive-compulsive, paranoid, schizoid, histrionic, and antisocial) were assessed in the Wave 1 NESARC. The sample size and high response rate of the Wave 2 NESARC allow for reliable and precise estimation of lifetime prevalence of BPD, especially among important sociodemographic subgroups of the population. Furthermore, comorbidity of BPD with each Axis I and II disorder was examined while controlling for both sociodemographic characteristics and additional psychiatric disorders to determine the unique relationship of each specific disorder to BPD. The importance of controlling for other disorders that are highly comorbid with one another represents an advance in our understanding of comorbidity recently highlighted in the epidemiologic literature.<sup>33,34</sup> The present study also provides information on mental and physical disability associated with BPD. Because so little is known about sex differences in BPD, information on correlates, disability, and comorbidity of BPD is presented for the total sample and by sex.

## METHOD

### Sample

The 2004–2005 Wave 2 NESARC<sup>30</sup> is the second wave following upon the Wave 1 NESARC, conducted in 2001–2002 and described in detail elsewhere.<sup>31,32</sup> The Wave 1 NESARC was a representative sample of the adult population of the United States. The target population was the civilian population, 18 years and older,

residing in households and group quarters. Face-to-face interviews were conducted with 43,093 respondents. The NESARC oversampled Blacks, Hispanics, and young adults aged 18 to 24 years. The overall response rate was 81.0%.

In Wave 2, attempts were made to conduct face-to-face reinterviews with all 43,093 respondents to the Wave 1 interview. Excluding respondents ineligible for the Wave 2 interview because they were deceased, deported, on active military duty throughout the follow-up period, or mentally or physically impaired, the Wave 2 response rate was 86.7%, reflecting 34,653 completed Wave 2 interviews. The cumulative response rate at Wave 2 was the product of the Wave 2 and Wave 1 response rates, or 70.2%. As in Wave 1, the Wave 2 NESARC data were weighted to reflect design characteristics of the survey and account for oversampling. Adjustment for nonresponse across sociodemographic characteristics and presence of any lifetime Wave 1 substance use disorder or psychiatric disorder was performed at the household and person levels. Weighted Wave 2 data were then adjusted to be representative of the civilian population on socioeconomic variables including region, age, race-ethnicity, and sex, based on the 2000 Decennial Census.

### Personality Disorders

Diagnoses were made using the Wave 2 Alcohol Use Disorder and Associated Disabilities Interview Schedule–DSM-IV Version (AUDADIS-IV),<sup>35,36</sup> a fully structured diagnostic interview designed for use by experienced lay interviewers. Avoidant, dependent, obsessive-compulsive, paranoid, schizoid, histrionic, and antisocial personality disorders were assessed in the Wave 1 NESARC and are described in detail elsewhere.<sup>37–39</sup> Borderline, schizotypal, and narcissistic personality disorders were assessed in Wave 2. These 3 personality disorders were not assessed in the Wave 1 NESARC due to their complexity and the associated number of symptom items necessary for their operationalization. All personality disorder diagnoses were assessed on a lifetime basis.

The diagnosis of personality disorders requires evaluation of long-term patterns of functioning.<sup>1</sup> Diagnoses of BPD in the AUDADIS-IV were made accordingly. All NESARC respondents were asked a series of BPD symptom questions about how they felt or acted most of the time throughout their lives, regardless of the situation or whom they were with. They were instructed not to include symptoms occurring only when they were depressed, manic, anxious, drinking heavily, using medicines or drugs, experiencing withdrawal symptoms (defined earlier in the interview), or physically ill. To receive a diagnosis of BPD, respondents had to endorse the requisite number of DSM-IV symptom items, at least 1 of which must have caused social or occupational dysfunction. Diagnoses for other personality disorders were made

similarly, except for antisocial personality disorder. Respondents needed to endorse the requisite numbers of both childhood symptoms before age 15 and symptoms of the adult antisocial syndrome since the age of 15.

Multiple symptom items were used to operationalize the more complex criteria associated with DSM-IV personality disorders, including BPD (18 items). Most personality disorder symptom items<sup>36</sup> were similar to those appearing in the Structured Clinical Interview for DSM-IV Personality Disorders,<sup>40</sup> the International Personality Disorder Examination,<sup>41</sup> and the Diagnostic Interview for DSM-IV Personality Disorders.<sup>42</sup>

The reliability of AUDADIS-IV personality disorder diagnoses and symptom scales was assessed in large test-retest studies conducted as part of the Wave 1<sup>43</sup> and Wave 2<sup>44</sup> NESARC surveys. Reliability of BPD was 0.71; reliabilities of other personality disorders ranged from fair to good ( $\kappa = 0.40\text{--}0.70$ ). Reliabilities of the associated symptom scales were much higher (intraclass correlation coefficients = 0.50–0.83). Reliabilities of AUDADIS-IV personality disorder diagnoses compare favorably with those found in short-term test-retest studies using semi-structured personality interviews in treated samples of patients.<sup>45</sup> Convergent validity of personality disorders assessed in Wave 1 was good to excellent and is reported in detail elsewhere.<sup>37–39</sup>

### Other Psychiatric Disorders

Wave 2 AUDADIS-IV measures of substance use (alcohol and drug-specific abuse and dependence and nicotine dependence), mood (major depressive disorder, dysthymia, bipolar I, and bipolar II), and anxiety (panic disorder with and without agoraphobia, social phobia, specific phobia, and generalized anxiety) disorders were identical to those utilized in Wave 1, except for the time frames. Wave 2 diagnoses of these disorders were made for 2 time periods between Waves 1 and 2: (1) the year preceding the Wave 2 interview and (2) the “intervening” period of approximately 2 years following the Wave 1 interview but before the year preceding the Wave 2 interview. For this study, 12-month diagnoses reflect disorders occurring during the year preceding the Wave 2 interview, while lifetime diagnoses reflect those occurring over the life course as assessed in both Wave 1 and Wave 2.

Extensive questions covered DSM-IV criteria for alcohol and drug-specific abuse and dependence, including sedatives, tranquilizers, opioids other than heroin, cannabis, cocaine or crack, stimulants, hallucinogens, inhalants and solvents, heroin, and other illicit drugs. Consistent with Wave 1 diagnoses, 12-month abuse required 1 or more of 4 abuse criteria and dependence required 3 or more of 7 dependence criteria to be met in the year preceding the Wave 2 interview. Similar to prior-to-the-past-year diagnoses in the Wave 1 NESARC, criteria for abuse or dependence during the intervening period must have

clustered within 1 year. Drug-specific abuse and dependence were aggregated in this study to yield diagnoses of any drug abuse and any drug dependence.

The reliability of AUDADIS-IV alcohol and drug diagnoses is documented in clinical and general population samples,<sup>43,44,46–49</sup> with test-retest reliability ranging from good to excellent ( $\kappa = 0.70\text{--}0.91$ ). Convergent, discriminant, and construct validity of AUDADIS-IV substance use disorder diagnoses were good to excellent,<sup>50–54</sup> including in the World Health Organization/National Institutes of Health International Study on Reliability and Validity,<sup>55–60</sup> in which clinical reappraisals documented good validity of DSM-IV alcohol and drug use disorder diagnoses ( $\kappa = 0.54\text{--}0.76$ ).<sup>46,55</sup>

Mood disorders included DSM-IV primary major depressive disorder (MDD), dysthymia, bipolar I disorder, and bipolar II disorder. Anxiety disorders included DSM-IV primary panic disorder with and without agoraphobia, social and specific phobias, and generalized anxiety disorder (GAD). A diagnosis of a mood disorder did not rule out an anxiety disorder, and in this sense these 2 types of diagnoses were nonhierarchical. AUDADIS-IV methods to diagnose these disorders are described in detail elsewhere.<sup>32,61–66</sup> In DSM-IV,<sup>1</sup> “primary” excludes substance-induced disorders and those due to general medical conditions. Diagnoses of MDD also ruled out bereavement. In addition, past-year and prior-to-the-past-year diagnoses of PTSD were assessed in the Wave 2 NESARC.

Test-retest reliabilities for AUDADIS-IV mood and anxiety disorder diagnoses in general population and clinical samples were fair to good ( $\kappa = 0.40\text{--}0.77$ ).<sup>43,44,46</sup> Convergent validity was good to excellent for all mood and anxiety diagnoses,<sup>61–66</sup> and selected diagnoses showed good agreement ( $\kappa = 0.64\text{--}0.68$ ) with psychiatrist reappraisals.<sup>46</sup>

### Disability

Disability was determined with the Short Form-12 Health Survey, version 2 (SF-12v2).<sup>67</sup> The SF-12v2 yields 8 profile scores that measure dimensions of physical and mental disability: social functioning, role emotional functioning (measuring role impairment), mental health, physical functioning, role physical functioning, bodily pain, general health, and vitality.

### Statistical Analysis

All analyses presented here were conducted for the total sample and by sex. Weighted frequencies and cross-tabulations were computed to calculate (1) lifetime prevalences of BPD by sociodemographic characteristics, (2) prevalences of BPD among respondents with other psychiatric disorders, and (3) prevalences of other psychiatric disorders among respondents with BPD. Adjusted odds ratios, derived from single multiple logistic regression analyses, assessed associations of BPD with

Table 1. Lifetime Prevalence and Odds Ratios of DSM-IV Borderline Personality Disorder and Sociodemographic Characteristics by Sex<sup>a</sup>

Characteristic	Total		Men		Women	
	% (SE)	OR (99% CI)	% (SE)	OR (99% CI)	% (SE)	OR (99% CI)
Total	5.9 (0.19)					
Sex						
Men	5.6 (0.24)	1.0 (0.83 to 1.12)				
Women	6.2 (0.25)					
Age						
20–29 y	9.3 (0.56)	<b>7.9</b> (5.69 to 10.83)	9.0 (0.79)	<b>5.8</b> (3.61 to 9.38)	9.6 (0.74)	<b>9.3</b> (5.90 to 14.57)
30–44 y	7.0 (0.37)	<b>6.7</b> (5.05 to 8.88)	6.1 (0.46)	<b>4.8</b> (3.11 to 7.41)	8.0 (0.49)	<b>8.3</b> (5.58 to 12.32)
45–64 y	5.5 (0.26)	<b>4.6</b> (3.43 to 6.20)	5.2 (0.39)	<b>3.7</b> (2.39 to 5.82)	5.7 (0.38)	<b>5.1</b> (3.48 to 7.62)
65+ y	2.0 (0.18)	1.0	2.1 (0.27)	1.0	2.0 (0.23)	1.0
Race-ethnicity						
White	5.6 (0.20)	1.0	5.1 (0.26)	1.0	6.0 (0.28)	1.0
Black	8.2 (0.50)	1.0 (0.80 to 1.20)	8.3 (0.69)	1.1 (0.85 to 1.48)	8.1 (0.60)	0.9 (0.70 to 1.13)
Native American	11.9 (1.54)	<b>1.8</b> (1.17 to 2.67)	13.2 (2.41)	<b>2.3</b> (1.26 to 4.07)	10.7 (1.92)	1.4 (0.80 to 2.55)
Asian	3.4 (0.72)	0.6 (0.30 to 1.03)	4.2 (1.26)	0.8 (0.34 to 1.86)	2.5 (0.66)	<b>0.4</b> (0.19 to 0.79)
Hispanic	5.3 (0.50)	<b>0.6</b> (0.44 to 0.81)	5.2 (0.64)	<b>0.6</b> (0.43 to 0.96)	5.3 (0.58)	<b>0.6</b> (0.39 to 0.82)
Family income						
\$0–\$19,999	9.8 (0.51)	<b>3.0</b> (2.28 to 4.02)	10.8 (0.79)	<b>3.3</b> (2.20 to 5.04)	9.1 (0.57)	<b>2.8</b> (1.90 to 4.05)
\$20,000–\$34,999	7.4 (0.38)	<b>2.3</b> (1.75 to 2.99)	7.4 (0.57)	<b>2.6</b> (1.69 to 3.88)	7.3 (0.46)	<b>2.0</b> (1.46 to 2.84)
\$35,000–\$69,999	5.2 (0.27)	<b>1.6</b> (1.22 to 2.00)	5.0 (0.36)	<b>1.7</b> (1.17 to 2.47)	5.3 (0.36)	<b>1.4</b> (1.03 to 1.98)
≥ \$70,000	3.1 (0.22)	1.0	2.7 (0.29)	1.0	3.7 (0.33)	1.0
Marital status						
Married/cohabiting	4.4 (0.18)	1.0	3.8 (0.24)	1.0	5.0 (0.26)	1.0
Separated/divorced/widowed	8.4 (0.41)	<b>1.9</b> (1.56 to 2.20)	10.1 (0.82)	<b>2.3</b> (1.70 to 3.11)	7.5 (0.40)	<b>1.7</b> (1.35 to 2.07)
Never married	8.7 (0.52)	1.2 (0.98 to 1.50)	8.7 (0.66)	1.4 (0.98 to 1.91)	8.8 (0.68)	1.1 (0.86 to 1.46)
Education						
Less than high school graduate	8.0 (0.50)	<b>1.6</b> (1.24 to 1.95)	8.9 (0.76)	<b>1.7</b> (1.23 to 2.44)	7.1 (0.59)	<b>1.4</b> (1.04 to 1.87)
High school graduate	6.8 (0.32)	<b>1.3</b> (1.10 to 1.56)	6.3 (0.45)	1.2 (0.96 to 1.62)	7.3 (0.44)	<b>1.4</b> (1.11 to 1.70)
Some college or higher	5.0 (0.21)	1.0	4.4 (0.26)	1.0	5.4 (0.28)	1.0
Urbanicity						
Urban	6.0 (0.21)	1.1 (0.85 to 1.35)	5.7 (0.26)	1.1 (0.80 to 1.57)	6.2 (0.28)	1.0 (0.76 to 1.39)
Rural	5.6 (0.41)	1.0	5.1 (0.54)	1.0	6.0 (0.55)	1.0
Region						
Northeast	6.0 (0.42)	1.0 (0.75 to 1.20)	5.3 (0.50)	0.8 (0.57 to 1.10)	6.7 (0.54)	1.1 (0.82 to 1.48)
Midwest	5.8 (0.36)	0.9 (0.75 to 1.17)	5.4 (0.49)	0.9 (0.62 to 1.21)	6.2 (0.51)	1.0 (0.73 to 1.36)
South	5.6 (0.27)	0.9 (0.73 to 1.06)	5.3 (0.32)	0.8 (0.61 to 1.05)	5.9 (0.36)	1.0 (0.75 to 1.21)
West	6.2 (0.32)	1.0	6.3 (0.45)	1.0	6.2 (0.44)	1.0

<sup>a</sup>Estimates in boldface are statistically significant ( $p < .01$ ).

sociodemographic characteristics. Chi-square statistics were used to determine sex differences in rates of co-occurrence of BPD with other psychiatric disorders.

Associations of BPD with psychiatric comorbidity were calculated 2 ways. The first controlled for sociodemographic characteristics, comparable with other reports on comorbidity. The second way further controlled for all other psychiatric disorders. This analysis addresses the fact that analyses controlling only for sociodemographic characteristics do not yield information on the unique relationships of BPD to other disorders that themselves have considerable comorbidity. Thus, control for other psychiatric disorders was necessary, as these disorders confound the relationship between BPD and each target diagnosis. Although these other comorbid disorders are also highly comorbid with one another, their introduction into the model did not invoke significant collinearity.

Multiple linear regression analyses examined the relationships of BPD with each of the 8 SF-12v2 disability scores, controlling for all sociodemographic characteristics and other psychiatric disorders, to determine

the independent contribution of BPD to disability. Analyses of physical disability scores also controlled for medical conditions. Standard norm-based scoring techniques were used to transform each score (range, 0–100) to achieve a mean of 50 and a standard deviation of 10 in the U.S. general population. Lower scores indicated more disability.

All standard errors and 99% confidence intervals were estimated using SUDAAN,<sup>68</sup> which adjusts for design characteristics of complex surveys like the NESARC.

## RESULTS

### Prevalence and Sociodemographic Characteristics

The prevalence of BPD in the NESARC sample was 5.9% (99% CI = 5.4 to 6.4). Rates of BPD did not differ significantly between men (5.6%; 99% CI = 5.0 to 6.2) and women (6.2%; 99% CI = 5.6 to 6.9). For the total sample, an inverse relationship of prevalence with age was observed, with the greatest decrease found after age 44 (Table 1). The odds of BPD were also significantly

Table 2. Co-Occurrence Rates of DSM-IV Lifetime Borderline Personality Disorder and Other 12-Month Psychiatric Disorders by Sex

Psychiatric Disorder	Prevalence of Borderline Personality Disorder Among Respondents With Other Psychiatric Disorder			Prevalence of Other Psychiatric Disorder Among Respondents With Borderline Personality Disorder		
	Total, % (SE)	Men, % (SE)	Women, % (SE)	Total, % (SE)	Men, % (SE)	Women, % (SE)
Any substance use disorder	14.1 (0.49)	12.2 (0.62)	16.9 (0.81) <sup>a</sup>	50.7 (1.33)	58.1 (2.15)	44.5 (1.76) <sup>a</sup>
Any substance abuse	11.6 (0.85)	10.6 (1.02)	14.6 (1.57)	12.9 (0.95)	18.6 (1.75)	8.2 (0.95) <sup>a</sup>
Any substance dependence	25.5 (1.30)	23.4 (1.47)	29.8 (2.60)	21.0 (1.06)	28.8 (1.66)	14.5 (1.32) <sup>a</sup>
Any alcohol use disorder	14.7 (0.76)	13.6 (0.86)	17.6 (1.55)	24.2 (1.18)	35.1 (1.91)	15.1 (1.29) <sup>a</sup>
Alcohol abuse	6.9 (0.67)	6.6 (0.78)	7.6 (1.23)	6.2 (0.62)	9.7 (1.17)	3.3 (0.55) <sup>a</sup>
Alcohol dependence	24.2 (1.36)	22.6 (1.57)	27.6 (2.61)	18.0 (1.01)	25.4 (1.64)	11.8 (1.14) <sup>a</sup>
Any drug use disorder	32.1 (2.07)	28.3 (2.40)	39.5 (3.76)	13.0 (0.95)	16.8 (1.57)	9.9 (1.26) <sup>a</sup>
Any drug abuse	26.5 (2.29)	22.8 (2.89)	34.9 (3.78)	7.7 (0.71)	10.0 (1.27)	5.7 (0.79) <sup>a</sup>
Any drug dependence	45.8 (3.99)	42.7 (4.65)	50.5 (6.53)	6.3 (0.68)	7.9 (1.05)	5.1 (0.99)
Nicotine dependence	15.4 (0.62)	13.6 (0.83)	17.6 (0.95) <sup>a</sup>	36.4 (1.22)	37.8 (1.94)	35.2 (1.70)
Any mood disorder	29.4 (0.92)	34.5 (1.66)	24.7 (1.10) <sup>a</sup>	50.9 (1.24)	45.2 (2.03)	55.7 (1.71) <sup>a</sup>
Major depressive disorder	19.9 (1.11)	24.5 (2.28)	18.0 (1.27)	19.3 (0.97)	15.4 (1.43)	22.5 (1.50) <sup>a</sup>
Dysthymia	36.3 (2.86)	34.6 (4.66)	37.1 (3.56)	7.2 (0.64)	4.8 (0.79)	9.2 (0.98) <sup>a</sup>
Bipolar I disorder	50.1 (1.87)	54.3 (3.52)	47.2 (2.21)	23.9 (1.13)	22.7 (1.90)	25.0 (1.40)
Bipolar II disorder	39.4 (3.57)	47.1 (6.28)	35.5 (4.05)	5.8 (0.65)	5.2 (0.94)	6.3 (0.85)
Any anxiety disorder	21.5 (0.69)	25.0 (1.27)	19.9 (0.79) <sup>a</sup>	59.6 (1.33)	50.1 (2.09)	67.6 (1.61) <sup>a</sup>
Panic with agoraphobia	51.0 (3.68)	43.1 (6.13)	54.2 (4.52)	6.9 (0.64)	3.6 (0.68)	9.6 (1.09) <sup>a</sup>
Panic without agoraphobia	26.9 (2.28)	32.4 (4.04)	24.0 (2.67)	8.1 (0.73)	7.3 (1.07)	8.8 (1.04)
Social phobia	40.6 (1.80)	40.2 (3.25)	40.9 (2.17)	17.5 (1.11)	15.0 (1.40)	19.5 (1.44)
Specific phobia	19.3 (0.96)	18.6 (1.72)	19.7 (1.07)	24.7 (1.17)	16.2 (1.40)	31.7 (1.61) <sup>a</sup>
Generalized anxiety disorder	35.6 (1.63)	43.5 (3.37)	32.2 (1.83) <sup>a</sup>	22.9 (1.13)	18.7 (1.60)	26.4 (1.57) <sup>a</sup>
Posttraumatic stress disorder	28.6 (1.16)	32.3 (2.58)	27.0 (1.14)	31.6 (1.21)	23.6 (1.74)	38.2 (1.66) <sup>a</sup>

<sup>a</sup>Significantly different from prevalence for men ( $p < .01$ ).

( $p < .01$ ) greater among Native Americans, but lower among Hispanics. Respondents in the 3 lowest income brackets (\$0–\$69,999) and those who were separated/divorced/widowed were more likely to have BPD. Further, the odds of BPD were greater among respondents with high school and less-than-high-school educations.

With few exceptions, results among men and women mirrored those found in the total sample. However, having less than a high school education was associated with increased odds of BPD among men. The odds of BPD were greater among Native American men and lower among Hispanic men and women and Asian women.

### Co-Occurrence of DSM-IV Lifetime Borderline Personality Disorder With Other 12-Month Psychiatric Disorders

Rates of co-occurrence of lifetime BPD with other 12-month psychiatric disorders are shown in Table 2 for the total sample and by sex. For the total sample, the prevalences of BPD among respondents with mood, anxiety, and substance use disorders were 29.4%, 21.5%, and 14.1%, respectively. Within these broad categories, rates of BPD were greatest among respondents with 12-month bipolar I disorder (50.1%), panic disorder with agoraphobia (51.0%), and any drug dependence (45.8%). The prevalence of BPD was significantly greater ( $p < .01$ ) among women with nicotine dependence (17.6%) than among men with nicotine dependence (13.6%). By contrast, the rates of BPD among men with GAD (43.5%), any anxiety disorder (25.0%), and any mood disorder (34.5%) were

greater than the corresponding rates among women (32.2%, 19.9%, and 26.7%, respectively).

Rates of any 12-month substance use, mood, and anxiety disorder among respondents with lifetime BPD were similar; 50.7%, 50.9%, and 59.6%, respectively. Alcohol dependence (18.0%), bipolar I (23.9%), and PTSD (31.6%) were the most prevalent disorders in their classes among respondents with BPD. Prevalences of all substance use disorders except drug dependence were significantly greater among men with BPD than among women with BPD, whereas women with BPD had significantly greater rates of all mood and anxiety disorders except bipolar I and II disorders, panic disorder without agoraphobia, and social phobia.

### Co-Occurrence of DSM-IV Lifetime Borderline Personality Disorder With Other Lifetime Psychiatric Disorders

Prevalences of BPD among respondents with other lifetime disorders were similar to the corresponding rates for 12-month disorders (Table 3). In the total sample, prevalences of BPD among respondents with lifetime mood, anxiety, and substance use disorders were 17.2%, 14.8%, and 9.5%, respectively. Bipolar I disorder (35.9%), panic disorder with agoraphobia (36.0%), and any drug dependence (30.9%) were the most prevalent disorders in their classes. Rates of BPD were consistently greater among men with any lifetime mood (19.0%) and any lifetime anxiety disorder (16.9%), compared with the corresponding rates among women (16.1%, 13.7%).

**Table 3. Co-Occurrence Rates of DSM-IV Lifetime Borderline Personality Disorder and Other Lifetime Psychiatric Disorders by Sex**

Psychiatric Disorder	Prevalence of Borderline Personality Disorder Among Respondents With Other Psychiatric Disorder			Prevalence of Other Psychiatric Disorder Among Respondents With Borderline Personality Disorder		
	Total, % (SE)	Men, % (SE)	Women, % (SE)	Total, % (SE)	Men, % (SE)	Women, % (SE)
Any substance use disorder	9.5 (0.31)	8.0 (0.37)	11.8 (0.51) <sup>a</sup>	72.9 (1.17)	80.9 (1.57)	66.2 (1.69) <sup>a</sup>
Any substance abuse	8.5 (0.37)	7.2 (0.44)	10.9 (0.66) <sup>a</sup>	37.8 (1.36)	46.7 (2.03)	30.5 (1.66) <sup>a</sup>
Any substance dependence	16.4 (0.66)	14.0 (0.77)	20.9 (1.17) <sup>a</sup>	45.3 (1.51)	55.5 (2.28)	36.8 (1.77) <sup>a</sup>
Any alcohol use disorder	9.8 (0.35)	8.3 (0.41)	12.5 (0.66) <sup>a</sup>	57.3 (1.43)	71.2 (1.93)	45.6 (1.89) <sup>a</sup>
Alcohol abuse	4.8 (0.33)	4.0 (0.37)	6.4 (0.56) <sup>a</sup>	15.7 (1.01)	18.9 (1.60)	12.9 (1.10) <sup>a</sup>
Alcohol dependence	16.1 (0.68)	13.9 (0.81)	20.3 (1.20) <sup>a</sup>	41.6 (1.52)	52.2 (2.36)	32.7 (1.74) <sup>a</sup>
Any drug use disorder	17.8 (0.77)	15.3 (0.95)	22.1 (1.43) <sup>a</sup>	36.2 (1.46)	44.0 (2.27)	29.8 (1.79) <sup>a</sup>
Any drug abuse	15.9 (0.79)	14.0 (0.98)	19.4 (1.34) <sup>a</sup>	27.4 (1.34)	34.6 (2.09)	21.3 (1.49) <sup>a</sup>
Any drug dependence	30.9 (1.87)	28.2 (2.32)	35.3 (3.05)	17.7 (1.17)	22.1 (1.95)	14.0 (1.31) <sup>a</sup>
Nicotine dependence	12.4 (0.47)	11.1 (0.62)	14.0 (0.68) <sup>a</sup>	48.6 (1.40)	52.1 (2.14)	45.7 (1.77)
Any mood disorder	17.2 (0.52)	19.0 (0.81)	16.1 (0.61) <sup>a</sup>	75.0 (1.11)	68.7 (1.88)	80.2 (1.42) <sup>a</sup>
Major depressive disorder	11.5 (0.52)	13.5 (0.95)	10.5 (0.61) <sup>a</sup>	32.1 (1.24)	27.2 (1.80)	36.1 (1.80) <sup>a</sup>
Dysthymia	16.7 (1.24)	17.0 (2.38)	16.5 (1.42)	9.7 (0.71)	7.1 (0.99)	11.9 (0.98) <sup>a</sup>
Bipolar I disorder	35.9 (1.47)	35.2 (2.35)	36.4 (1.66)	31.8 (1.25)	30.6 (2.06)	32.7 (1.59)
Bipolar II disorder	26.7 (2.16)	26.6 (3.26)	26.8 (2.74)	7.7 (0.73)	6.7 (1.08)	8.5 (0.92)
Any anxiety disorder	14.8 (0.46)	16.9 (0.80)	13.7 (0.54) <sup>a</sup>	74.2 (1.24)	66.1 (2.04)	81.1 (1.31) <sup>a</sup>
Panic with agoraphobia	36.0 (2.31)	37.9 (4.39)	35.2 (2.75)	11.5 (0.89)	7.7 (1.12)	14.6 (1.30) <sup>a</sup>
Panic without agoraphobia	18.9 (1.10)	22.9 (1.98)	17.0 (1.24)	18.8 (1.01)	16.2 (1.38)	20.9 (1.42)
Social phobia	24.5 (1.09)	23.5 (1.74)	25.2 (1.40)	29.3 (1.33)	25.2 (1.73)	32.7 (1.81) <sup>a</sup>
Specific phobia	14.6 (0.62)	14.5 (1.05)	14.6 (0.74)	37.5 (1.44)	26.6 (1.77)	46.6 (1.91) <sup>a</sup>
Generalized anxiety disorder	27.0 (1.02)	30.5 (2.00)	25.4 (1.17)	35.1 (1.29)	27.3 (1.89)	41.6 (1.68) <sup>a</sup>
Posttraumatic stress disorder	24.3 (0.93)	27.7 (1.90)	22.9 (0.98)	39.2 (1.31)	29.5 (1.80)	47.2 (1.81) <sup>a</sup>
Any other personality disorder	21.8 (0.64)	19.5 (0.83)	24.4 (0.93) <sup>a</sup>	73.9 (1.17)	76.5 (1.70)	71.8 (1.47)
Any cluster A	33.0 (1.13)	31.1 (1.51)	34.7 (1.51)	50.4 (1.38)	49.5 (2.06)	51.1 (1.71)
Paranoid	29.0 (1.47)	24.9 (2.28)	31.8 (1.86)	21.3 (1.17)	16.5 (1.57)	25.4 (1.56) <sup>a</sup>
Schizoid	23.8 (1.54)	20.0 (2.12)	27.5 (2.20)	12.4 (0.86)	11.1 (1.25)	13.5 (1.12)
Schizotypal	54.9 (1.72)	51.3 (2.40)	58.8 (2.42)	36.7 (1.37)	38.9 (2.04)	34.9 (1.60)
Any other cluster B	28.2 (0.94)	24.3 (1.18)	34.5 (1.54) <sup>a</sup>	49.2 (1.45)	57.8 (2.23)	42.1 (1.80) <sup>a</sup>
Antisocial	21.0 (1.40)	18.3 (1.62)	28.7 (2.79) <sup>a</sup>	13.7 (0.96)	19.4 (1.64)	9.0 (0.97) <sup>a</sup>
Histrionic	33.6 (2.26)	31.1 (3.43)	36.0 (2.97)	10.3 (0.84)	10.3 (1.43)	10.3 (0.99)
Narcissistic	37.0 (1.29)	34.2 (1.63)	41.3 (2.01) <sup>a</sup>	38.9 (1.44)	47.0 (2.23)	32.2 (1.71) <sup>a</sup>
Any cluster C	18.6 (0.85)	16.4 (1.24)	20.5 (1.17)	29.9 (1.29)	27.0 (1.85)	32.3 (1.71)
Avoidant	34.0 (2.13)	31.6 (3.73)	35.5 (2.39)	13.4 (0.94)	10.8 (1.37)	15.6 (1.32)
Dependent	42.6 (4.57)	45.7 (8.92)	40.8 (5.67)	3.1 (0.47)	2.6 (0.77)	3.5 (0.62)
Obsessive-compulsive	16.6 (0.90)	14.9 (1.18)	18.1 (1.36)	22.7 (1.23)	21.7 (1.57)	23.6 (1.65)

<sup>a</sup>Significantly different from prevalence for men ( $p < .01$ ).

Conversely, rates of BPD were greater among women than among men with all substance use disorders except drug dependence.

Prevalence of BPD among women with any other lifetime personality disorder was 24.4%, greater than the corresponding rate among men (19.5%). However, rates of BPD among women with antisocial and narcissistic personality disorders were greater than the rates of BPD among men with these personality disorders.

The patterns of co-occurrence between lifetime BPD and other lifetime psychiatric disorders in the total sample mirrored those observed for 12-month comorbid disorders, with 2 notable exceptions. MDD (32.1%) and bipolar I disorder (31.8%) were the most prevalent mood disorders and specific phobia (37.5%), GAD (35.1%), and PTSD (39.2%) were the most prevalent anxiety disorders among respondents with BPD. Generally consistent with the 12-month findings, rates of substance use disorders except nicotine dependence were greater among men than among women with BPD, whereas rates of MDD and dysthymia and anxiety disorders except panic disorder with-

out agoraphobia were greater among women than among men with BPD. Rates of antisocial and narcissistic personality disorders were greater among men with BPD than among women with BPD.

#### **Associations Between Lifetime Borderline Personality Disorder and Other 12-Month and Lifetime Psychiatric Disorders, Controlling for Sociodemographic Characteristics and Other Psychiatric Disorders**

Associations between lifetime BPD and other lifetime disorders controlling for sociodemographic characteristics and additional comorbid disorders are depicted in Table 4. When only sociodemographic characteristics were controlled for, 99.0% of all associations between BPD and other psychiatric disorders were positive and significant, both for the total sample and among men and women. The only exception was alcohol abuse, which was negatively associated with BPD among men. In the total sample, BPD was most strongly related to any drug dependence, bipolar I disorder, panic disorder with

Table 4. Odds Ratios of Lifetime DSM-IV Borderline Personality Disorder and Other Lifetime Psychiatric Disorders by Sex<sup>a</sup>

Psychiatric Disorder	Odds Ratios Controlled for Sociodemographic Characteristics			Odds Ratios Controlled for Sociodemographic Characteristics and Other Psychiatric Disorders		
	Total, OR (99% CI)	Men, OR (99% CI)	Women, OR (99% CI)	Total, OR (99% CI)	Men, OR (99% CI)	Women, OR (99% CI)
Any substance use disorder	<b>3.2</b> (2.73 to 3.79)	<b>3.0</b> (2.26 to 3.96)	<b>3.3</b> (2.69 to 4.07)	<b>1.7</b> (1.43 to 2.02)	<b>1.7</b> (1.25 to 2.24)	<b>1.7</b> (1.34 to 2.1)
Any substance abuse	<b>1.7</b> (1.46 to 2.03)	<b>1.6</b> (1.23 to 2.00)	<b>1.9</b> (1.51 to 2.32)	<b>1.2</b> (0.96 to 1.39)	<b>1.2</b> (0.88 to 1.57)	<b>1.1</b> (0.87 to 1.45)
Any substance dependence	<b>4.2</b> (3.59 to 5.01)	<b>4.0</b> (3.11 to 5.15)	<b>4.5</b> (3.63 to 5.63)	<b>1.7</b> (1.43 to 2.12)	<b>1.8</b> (1.30 to 2.38)	<b>1.7</b> (1.32 to 2.27)
Any alcohol use disorder	<b>2.7</b> (2.33 to 3.16)	<b>2.7</b> (2.07 to 3.45)	<b>2.7</b> (2.21 to 3.33)	<b>1.2</b> (1.00 to 1.48)	<b>1.3</b> (0.96 to 1.74)	<b>1.1</b> (0.86 to 1.45)
Alcohol abuse	0.8 (0.64 to 1.00)	<b>0.7</b> (0.50 to 0.93)	0.9 (0.71 to 1.22)	0.9 (0.73 to 1.18)	1.0 (0.68 to 1.38)	0.8 (0.62 to 1.15)
Alcohol dependence	<b>3.9</b> (3.33 to 4.64)	<b>3.8</b> (2.91 to 4.86)	<b>4.2</b> (3.31 to 5.26)	<b>1.5</b> (1.17 to 1.86)	<b>1.5</b> (1.09 to 2.16)	<b>1.4</b> (1.02 to 1.96)
Any drug use disorder	<b>4.0</b> (3.30 to 4.72)	<b>3.7</b> (2.85 to 4.72)	<b>4.2</b> (3.27 to 5.50)	<b>1.5</b> (1.22 to 1.96)	<b>1.4</b> (1.01 to 1.99)	<b>1.7</b> (1.25 to 2.42)
Any drug abuse	<b>3.1</b> (2.51 to 3.74)	<b>2.9</b> (2.22 to 3.88)	<b>3.3</b> (2.50 to 4.29)	<b>1.4</b> (1.09 to 1.77)	<b>1.3</b> (0.94 to 1.81)	<b>1.5</b> (1.11 to 2.14)
Any drug dependence	<b>6.1</b> (4.66 to 7.93)	<b>6.0</b> (4.15 to 8.54)	<b>6.3</b> (4.30 to 9.23)	<b>1.4</b> (1.00 to 1.96)	<b>1.4</b> (0.94 to 2.21)	<b>1.4</b> (0.86 to 2.21)
Nicotine dependence	<b>2.8</b> (2.37 to 3.26)	<b>2.6</b> (2.08 to 3.32)	<b>2.9</b> (2.33 to 3.54)	<b>1.3</b> (1.05 to 1.55)	<b>1.2</b> (0.88 to 1.61)	<b>1.3</b> (1.04 to 1.71)
Any mood disorder	<b>9.1</b> (7.71 to 10.78)	<b>9.0</b> (7.02 to 11.48)	<b>9.3</b> (7.27 to 11.87)	<b>1.7</b> (1.40 to 2.09)	<b>3.4</b> (2.56 to 4.57)	<b>3.6</b> (2.75 to 4.63)
Major depressive disorder	<b>2.5</b> (2.07 to 2.90)	<b>3.0</b> (2.27 to 3.89)	<b>2.1</b> (1.72 to 2.66)	<b>1.7</b> (1.40 to 2.09)	<b>2.0</b> (1.46 to 2.68)	<b>1.6</b> (1.23 to 2.00)
Dysthymia	<b>3.2</b> (2.51 to 4.16)	<b>3.3</b> (2.04 to 5.45)	<b>3.2</b> (2.45 to 4.27)	<b>1.1</b> (0.85 to 1.53)	<b>1.1</b> (0.65 to 1.99)	<b>1.1</b> (0.81 to 1.60)
Bipolar I disorder	<b>9.9</b> (8.11 to 12.01)	<b>10.3</b> (7.41 to 14.33)	<b>9.6</b> (7.57 to 12.14)	<b>5.7</b> (4.41 to 7.25)	<b>5.2</b> (3.48 to 7.61)	<b>6.2</b> (4.54 to 8.56)
Bipolar II disorder	<b>4.3</b> (3.00 to 6.03)	<b>4.6</b> (2.81 to 7.37)	<b>4.1</b> (2.59 to 6.43)	<b>4.3</b> (2.85 to 6.40)	<b>4.3</b> (2.32 to 7.94)	<b>4.4</b> (2.56 to 7.42)
Any anxiety disorder	<b>7.7</b> (6.51 to 9.19)	<b>7.8</b> (6.09 to 9.99)	<b>7.7</b> (6.13 to 9.69)	<b>2.7</b> (2.22 to 3.35)	<b>2.8</b> (2.12 to 3.79)	<b>2.6</b> (2.01 to 3.40)
Panic with agoraphobia	<b>8.4</b> (6.26 to 11.18)	<b>9.1</b> (5.38 to 15.53)	<b>8.1</b> (5.74 to 11.34)	<b>1.8</b> (1.31 to 2.46)	<b>1.7</b> (0.89 to 3.15)	<b>1.9</b> (1.28 to 2.73)
Panic without agoraphobia	<b>4.0</b> (3.25 to 4.85)	<b>5.7</b> (4.15 to 7.77)	<b>3.3</b> (2.53 to 4.16)	<b>1.4</b> (1.08 to 1.77)	<b>1.8</b> (1.19 to 2.82)	<b>1.2</b> (0.88 to 1.61)
Social phobia	<b>6.2</b> (5.24 to 7.41)	<b>6.2</b> (4.60 to 8.24)	<b>6.3</b> (5.01 to 7.88)	<b>1.7</b> (1.35 to 2.04)	<b>1.6</b> (1.09 to 2.28)	<b>1.7</b> (1.32 to 2.21)
Specific phobia	<b>3.8</b> (2.97 to 4.09)	<b>3.2</b> (2.48 to 4.22)	<b>3.7</b> (3.03 to 4.43)	<b>1.2</b> (0.99 to 1.44)	<b>1.1</b> (0.77 to 1.44)	<b>1.3</b> (1.07 to 1.64)
Generalized anxiety disorder	<b>8.3</b> (6.95 to 9.85)	<b>9.2</b> (6.74 to 12.42)	<b>7.8</b> (6.34 to 9.63)	<b>2.3</b> (1.88 to 2.82)	<b>2.4</b> (1.67 to 3.36)	<b>2.3</b> (1.76 to 2.90)
Posttraumatic stress disorder	<b>7.3</b> (6.11 to 8.65)	<b>8.0</b> (6.08 to 10.55)	<b>6.9</b> (5.60 to 8.52)	<b>2.7</b> (2.20 to 3.23)	<b>2.7</b> (1.94 to 3.73)	<b>2.7</b> (2.10 to 3.39)
Any other personality disorder	<b>12.5</b> (10.54 to 14.86)	<b>12.4</b> (9.44 to 16.18)	<b>13.0</b> (10.57 to 15.86)	<b>5.8</b> (4.73 to 7.01)	<b>5.7</b> (4.20 to 7.74)	<b>6.0</b> (4.81 to 7.43)
Any cluster A	<b>12.1</b> (10.14 to 14.34)	<b>11.4</b> (8.82 to 14.62)	<b>12.9</b> (10.43 to 15.96)	<b>3.9</b> (3.07 to 4.89)	<b>3.4</b> (2.40 to 4.91)	<b>4.4</b> (3.27 to 5.82)
Paranoid	<b>5.8</b> (4.69 to 7.25)	<b>4.6</b> (3.11 to 6.66)	<b>6.9</b> (5.38 to 8.84)	<b>1.2</b> (0.93 to 1.53)	<b>0.9</b> (0.57 to 1.31)	<b>1.5</b> (1.09 to 1.94)
Schizoid	<b>4.5</b> (3.55 to 5.76)	<b>3.8</b> (2.62 to 5.64)	<b>5.2</b> (3.82 to 7.08)	<b>1.0</b> (0.75 to 1.32)	<b>0.8</b> (0.51 to 1.22)	<b>1.2</b> (0.85 to 1.67)
Schizotypal	<b>26.5</b> (21.53 to 32.68)	<b>23.6</b> (17.35 to 31.96)	<b>31.3</b> (23.51 to 41.52)	<b>9.4</b> (7.40 to 11.95)	<b>8.5</b> (5.89 to 12.13)	<b>11.0</b> (7.79 to 15.39)
Any other cluster B	<b>10.1</b> (8.52 to 11.98)	<b>9.6</b> (7.30 to 12.60)	<b>11.1</b> (8.88 to 13.84)	<b>3.8</b> (3.06 to 4.74)	<b>3.8</b> (2.72 to 5.25)	<b>4.1</b> (3.08 to 5.39)
Antisocial	<b>3.5</b> (2.71 to 4.40)	<b>3.3</b> (2.40 to 4.54)	<b>3.9</b> (2.68 to 5.73)	<b>1.0</b> (0.71 to 1.27)	<b>0.9</b> (0.62 to 1.33)	<b>1.0</b> (0.66 to 1.58)
Histrionic	<b>6.5</b> (4.90 to 8.52)	<b>6.1</b> (3.90 to 9.39)	<b>6.9</b> (4.67 to 10.04)	<b>1.4</b> (1.01 to 1.89)	<b>1.2</b> (0.75 to 1.86)	<b>1.6</b> (1.03 to 2.38)
Narcissistic	<b>14.5</b> (12.12 to 17.42)	<b>14.5</b> (10.96 to 19.09)	<b>15.3</b> (11.92 to 19.57)	<b>7.5</b> (6.00 to 9.27)	<b>7.6</b> (5.46 to 10.65)	<b>7.8</b> (5.77 to 10.44)
Any cluster C	<b>4.5</b> (3.76 to 5.28)	<b>4.0</b> (3.05 to 5.29)	<b>4.9</b> (3.91 to 6.06)	<b>0.9</b> (0.71 to 1.13)	<b>0.8</b> (0.52 to 1.03)	<b>1.0</b> (0.72 to 1.34)
Avoidant	<b>7.2</b> (5.45 to 9.56)	<b>6.5</b> (3.95 to 10.77)	<b>7.6</b> (5.58 to 10.38)	<b>1.4</b> (1.03 to 1.84)	<b>1.2</b> (0.71 to 2.03)	<b>1.4</b> (1.02 to 2.03)
Dependent	<b>8.2</b> (4.65 to 14.46)	<b>8.8</b> (3.09 to 24.96)	<b>7.3</b> (3.84 to 15.94)	<b>1.2</b> (0.67 to 2.15)	<b>1.1</b> (0.38 to 3.13)	<b>1.2</b> (0.57 to 2.59)
Obsessive-compulsive	<b>3.7</b> (3.06 to 4.52)	<b>3.5</b> (2.60 to 4.62)	<b>4.0</b> (3.05 to 5.19)	<b>0.9</b> (0.72 to 1.12)	<b>0.8</b> (0.58 to 1.14)	<b>1.0</b> (0.70 to 1.32)

<sup>a</sup>Estimates in boldface are statistically significant (p < .01).

**Table 5. Odds Ratios of Lifetime DSM-IV Borderline Personality Disorder and Other 12-Month Psychiatric Disorders by Sex<sup>a</sup>**

Psychiatric Disorder	Odds Ratios Controlled for Sociodemographic Characteristics			Odds Ratios Controlled for Sociodemographic Characteristics and Other Psychiatric Disorders		
	Total, OR (99% CI)	Men, OR (99% CI)	Women, OR (99% CI)	Total, OR (99% CI)	Men, OR (99% CI)	Women, OR (99% CI)
Any substance use disorder	<b>3.4</b> (2.89 to 3.93)	<b>3.2</b> (2.51 to 4.10)	<b>3.5</b> (2.84 to 4.30)	<b>1.9</b> (1.61 to 2.29)	<b>1.9</b> (1.46 to 2.56)	<b>1.9</b> (1.48 to 2.4)
Any substance abuse	<b>1.8</b> (1.37 to 2.32)	<b>1.8</b> (1.28 to 2.54)	<b>1.8</b> (1.27 to 2.66)	<b>1.4</b> (1.04 to 1.92)	<b>1.5</b> (1.01 to 2.26)	<b>1.3</b> (0.76 to 2.06)
Any substance dependence	<b>4.9</b> (4.00 to 5.95)	<b>4.7</b> (3.68 to 6.08)	<b>5.3</b> (3.75 to 7.45)	<b>2.3</b> (1.73 to 2.94)	<b>2.4</b> (1.74 to 3.33)	<b>2.1</b> (1.35 to 3.33)
Any alcohol use disorder	<b>2.7</b> (2.22 to 3.25)	<b>2.8</b> (2.20 to 3.56)	<b>2.6</b> (1.90 to 3.59)	<b>1.6</b> (1.20 to 2.02)	<b>1.7</b> (1.24 to 2.36)	<b>1.4</b> (0.88 to 2.16)
Alcohol abuse	1.0 (0.71 to 1.32)	1.1 (0.72 to 1.53)	0.9 (0.52 to 1.41)	<b>1.6</b> (0.68 to 1.51)	1.2 (0.72 to 1.91)	0.8 (0.37 to 1.59)
Alcohol dependence	<b>4.4</b> (3.62 to 5.44)	<b>4.4</b> (3.39 to 5.63)	<b>4.7</b> (3.27 to 6.77)	<b>2.1</b> (1.52 to 2.76)	<b>2.3</b> (1.59 to 3.20)	<b>1.9</b> (1.09 to 3.13)
Any drug use disorder	<b>5.6</b> (4.14 to 7.46)	<b>5.0</b> (3.45 to 7.33)	<b>6.7</b> (4.25 to 10.39)	<b>2.0</b> (1.32 to 3.05)	<b>1.9</b> (1.09 to 3.28)	<b>2.2</b> (1.20 to 3.84)
Any drug abuse	<b>4.0</b> (2.79 to 5.61)	<b>3.5</b> (2.11 to 5.64)	<b>5.1</b> (3.15 to 8.35)	<b>1.9</b> (1.16 to 3.04)	<b>1.7</b> (0.87 to 3.19)	<b>2.3</b> (1.13 to 4.71)
Any drug dependence	<b>8.8</b> (5.45 to 14.08)	<b>8.1</b> (4.51 to 14.63)	<b>9.6</b> (4.73 to 19.62)	<b>1.8</b> (0.91 to 3.37)	<b>1.8</b> (0.79 to 4.29)	<b>1.6</b> (0.68 to 3.96)
Nicotine dependence	<b>3.0</b> (2.57 to 3.57)	<b>2.7</b> (2.14 to 3.45)	<b>3.3</b> (2.63 to 4.13)	<b>1.5</b> (1.25 to 1.89)	<b>1.5</b> (1.07 to 1.97)	<b>1.6</b> (1.21 to 2.07)
Any mood disorder	<b>10.6</b> (9.04 to 12.39)	<b>12.4</b> (9.39 to 16.28)	<b>9.4</b> (7.69 to 11.53)	<b>4.2</b> (3.44 to 5.11)	<b>4.5</b> (3.23 to 6.29)	<b>4.0</b> (3.17 to 5.07)
Major depressive disorder	<b>4.1</b> (3.38 to 5.07)	<b>5.2</b> (3.61 to 7.54)	<b>3.6</b> (2.83 to 4.67)	<b>2.6</b> (2.02 to 3.35)	<b>2.6</b> (1.67 to 4.11)	<b>2.6</b> (1.89 to 3.55)
Dysthymia	<b>7.9</b> (5.59 to 11.18)	<b>6.9</b> (3.77 to 12.61)	<b>8.6</b> (5.66 to 13.01)	<b>1.5</b> (0.91 to 2.46)	<b>1.0</b> (0.45 to 2.20)	<b>1.9</b> (1.01 to 3.51)
Bipolar I disorder	<b>16.0</b> (12.75 to 20.08)	<b>20.6</b> (13.19 to 32.02)	<b>11.5</b> (10.40 to 17.64)	<b>6.5</b> (4.93 to 8.50)	<b>7.5</b> (4.35 to 12.81)	<b>5.9</b> (4.32 to 7.97)
Bipolar II disorder	<b>7.5</b> (4.69 to 11.94)	<b>10.5</b> (5.14 to 21.33)	<b>6.3</b> (3.51 to 11.26)	<b>4.9</b> (2.86 to 8.37)	<b>6.4</b> (2.67 to 15.44)	<b>4.3</b> (2.24 to 8.30)
Any anxiety disorder	<b>8.5</b> (7.39 to 10.34)	<b>9.2</b> (7.03 to 11.95)	<b>8.5</b> (6.85 to 10.42)	<b>3.3</b> (2.62 to 4.03)	<b>3.4</b> (2.42 to 4.64)	<b>3.2</b> (2.43 to 4.13)
Panic with agoraphobia	<b>13.7</b> (8.91 to 20.93)	<b>10.9</b> (4.95 to 23.83)	<b>15.1</b> (9.00 to 25.25)	<b>2.1</b> (1.17 to 3.58)	<b>1.2</b> (0.42 to 3.31)	<b>2.6</b> (1.37 to 5.07)
Panic without agoraphobia	<b>5.2</b> (3.70 to 7.20)	<b>7.6</b> (4.27 to 13.50)	<b>4.2</b> (2.78 to 6.24)	<b>1.5</b> (0.97 to 2.36)	<b>2.0</b> (0.93 to 4.33)	<b>1.3</b> (0.77 to 2.26)
Social phobia	<b>10.7</b> (8.53 to 13.52)	<b>10.9</b> (7.36 to 16.20)	<b>10.6</b> (7.95 to 14.14)	<b>2.3</b> (1.67 to 3.02)	<b>2.0</b> (1.22 to 3.37)	<b>2.4</b> (1.65 to 3.44)
Specific phobia	<b>4.3</b> (3.55 to 5.22)	<b>4.0</b> (2.84 to 5.62)	<b>4.5</b> (3.60 to 5.60)	<b>1.6</b> (1.22 to 2.03)	<b>1.2</b> (0.78 to 1.95)	<b>1.8</b> (1.38 to 2.38)
Generalized anxiety disorder	<b>10.4</b> (8.22 to 13.19)	<b>13.8</b> (8.85 to 21.46)	<b>9.0</b> (6.89 to 11.84)	<b>2.4</b> (1.80 to 3.24)	<b>2.7</b> (1.60 to 4.70)	<b>2.3</b> (1.59 to 3.17)
Posttraumatic stress disorder	<b>7.9</b> (6.54 to 9.53)	<b>9.0</b> (6.29 to 13.00)	<b>7.4</b> (6.06 to 9.10)	<b>2.5</b> (2.00 to 3.19)	<b>2.5</b> (1.56 to 4.05)	<b>2.5</b> (1.97 to 3.27)
Any other personality disorder	...	...	...	<b>7.0</b> (5.75 to 8.50)	<b>7.1</b> (5.24 to 9.61)	<b>7.1</b> (5.68 to 8.87)
Any cluster A	...	...	...	<b>4.2</b> (3.26 to 5.35)	<b>3.7</b> (2.55 to 5.50)	<b>4.7</b> (3.44 to 6.29)
Paranoid	...	...	...	<b>1.5</b> (1.12 to 1.95)	<b>1.2</b> (0.75 to 1.93)	<b>1.7</b> (1.23 to 2.28)
Schizoid	...	...	...	<b>1.2</b> (0.86 to 1.60)	<b>1.0</b> (0.59 to 1.59)	<b>1.4</b> (0.95 to 1.93)
Schizotypal	...	...	...	<b>8.3</b> (6.41 to 10.85)	<b>7.3</b> (4.91 to 10.99)	<b>9.9</b> (6.92 to 14.1)
Any other cluster B	...	...	...	<b>4.2</b> (3.31 to 5.21)	<b>4.1</b> (2.91 to 5.79)	<b>4.4</b> (3.31 to 5.89)
Antisocial	...	...	...	<b>1.2</b> (0.87 to 1.65)	<b>1.2</b> (0.78 to 1.76)	<b>1.2</b> (0.75 to 2.03)
Histrionic	...	...	...	<b>1.7</b> (1.20 to 2.32)	<b>1.5</b> (0.94 to 2.42)	<b>1.8</b> (1.17 to 2.73)
Narcissistic	...	...	...	<b>6.8</b> (5.43 to 8.46)	<b>6.9</b> (4.86 to 9.69)	<b>7.1</b> (5.17 to 9.62)
Any cluster C	...	...	...	<b>1.1</b> (0.87 to 1.47)	<b>1.1</b> (0.71 to 1.64)	<b>1.2</b> (0.83 to 1.63)
Avoidant	...	...	...	<b>1.6</b> (1.16 to 2.33)	<b>1.7</b> (0.87 to 3.19)	<b>1.6</b> (1.06 to 2.27)
Dependent	...	...	...	<b>1.3</b> (0.64 to 2.43)	<b>1.3</b> (0.40 to 4.00)	<b>1.2</b> (0.48 to 2.83)
Obsessive-compulsive	...	...	...	<b>1.1</b> (0.85 to 1.41)	<b>1.1</b> (0.74 to 1.60)	<b>1.1</b> (0.77 to 1.55)

<sup>a</sup>Estimates in boldface are statistically significant (p < .01).



Table 6. Associations<sup>a</sup> Between Lifetime Borderline Personality Disorder and Mental and Physical Disability

SF12-v2 Score	Total		Men		Women	
	Mean (SE)	$\beta$ (SE)	Mean (SE)	$\beta$ (SE)	Mean (SE)	$\beta$ (SE)
Mental disability						
Social functioning	42.8 (0.37)	-5.0 (0.39)*	44.3 (0.59)	-4.3 (0.60)*	41.5 (0.46)	-5.5 (0.50)*
Role emotional functioning	41.6 (0.36)	-4.9 (0.38)*	42.5 (0.55)	-4.4 (0.59)*	39.7 (0.46)	-5.2 (0.53)*
Mental health	41.7 (0.34)	-5.3 (0.37)*	43.3 (0.54)	-5.3 (0.60)*	40.4 (0.39)	-5.3 (0.47)*
Physical disability						
Physical functioning	47.5 (0.34)	-1.3 (0.32)*	48.7 (0.48)	-1.0 (0.46)†	46.5 (0.44)	-1.4 (0.46)*
Role physical functioning	44.9 (0.32)	-2.3 (0.31)*	45.9 (0.46)	-2.0 (0.49)*	44.2 (0.41)	-2.6 (0.42)†
Bodily pain	44.9 (0.36)	-1.9 (0.37)*	46.1 (0.53)	-1.1 (0.52)†	43.9 (0.50)	-2.5 (0.54)*
General health	44.1 (0.37)	-2.1 (0.39)*	44.2 (0.57)	-2.3 (0.57)*	43.9 (0.45)	-2.0 (0.48)†
Vitality	46.5 (0.32)	-2.6 (0.35)*	48.4 (0.50)	-2.2 (0.56)*	45.0 (0.41)	-2.7 (0.47)*

<sup>a</sup>Multiple linear regression analyses controlled for all sociodemographic characteristics and other Axis I and II psychiatric disorders. Medical conditions were additionally controlled for in analyses related to physical disability scores.

\* $p < .0002$ .

† $p < .03$ .

agoraphobia, GAD, social phobia, and PTSD, and schizotypal, narcissistic, and dependent personality disorders. Results were similar among men and women.

Odds ratios were reduced when additional comorbidity was controlled for. For the total sample, associations of lifetime BPD with bipolar I and II disorders and schizotypal and narcissistic personality disorders were reduced but remained strong and statistically and clinically significant (odds ratios  $\geq 4.3$ ). Lifetime BPD also remained associated with alcohol dependence, any drug abuse, nicotine dependence, MDD, panic disorder with and without agoraphobia, social phobia, GAD, PTSD, and histrionic and avoidant personality disorders, but with lower odds ratios that may not be clinically significant. These results were generally consistent among men and women, with the following notable exceptions. BPD remained significantly, but less strongly, associated with panic disorder without agoraphobia among men but not women. By contrast, associations of BPD with any drug abuse, nicotine dependence, panic disorder with agoraphobia, and histrionic and avoidant personality disorders remained significant, but modest, only among women. In addition, specific phobia and paranoid personality disorder were significantly, but modestly, associated with BPD among women, a result not observed in the total sample or among men.

With few exceptions, patterns of associations between lifetime BPD and other lifetime psychiatric disorders were remarkably similar to those found for 12-month comorbid disorders (Table 5).

### Disability

Borderline personality disorder was highly and significantly related to each SF-12v2 disability score (Table 6). Respondents with lifetime BPD had greater disability than those without BPD, even when sociodemographic characteristics, medical conditions (for physical disability analyses), and other Axis I and II psychiatric disorders were controlled for. The medical conditions measure was entered into the model as the number of medical conditions

that included arteriosclerosis, hypertension, diabetes, cirrhosis of the liver, other forms of liver disease, angina pectoris, tachycardia, myocardial infarction, high cholesterol, other forms of heart disease, stomach ulcer, human immunodeficiency virus–seropositivity, acquired immunodeficiency syndrome, other sexually transmitted disease, gastritis, arthritis, and stroke. The severity of mental disability was greater than that associated with physical disability. Women with BPD had significantly greater disability ( $p < .01$ ) than men with BPD as assessed by each SF-12v2 score.

## DISCUSSION

The prevalence of BPD was 5.9% in this general population sample, approximating values in the upper range of estimates (0.0%–5.4%) found in previous epidemiologic surveys.<sup>13–29</sup> The discrepancy in rates of BPD between this study and others may be partly due to limitations of prior surveys with respect to unrepresentative samples and small sample sizes. Differences in diagnostic criteria, assessment instruments, and survey designs and methodologies may also have contributed to the discrepancies.

Consistent with most epidemiologic surveys,<sup>15,19,27–29</sup> but not clinical studies,<sup>69</sup> the prevalence of BPD did not differ by sex. Although greater rates of BPD among women in clinical studies have been attributed to increases in criterion or assessment biases, research on these biases in the clinical diagnosis of BPD has been equivocal.<sup>70,71</sup> Increased rates of BPD among women in clinical samples might also reflect increased treatment seeking among women with BPD, sampling biases,<sup>72</sup> or biological or sociocultural differences,<sup>70</sup> explanations that have not yet been thoroughly investigated.

Despite the sex difference in BPD observed in general population and clinical samples, this study found striking similarities to recent clinical research on sex differences in rates of co-occurrence of BPD. Consistent with this research,<sup>9,71,73–76</sup> the prevalences in the present study of

substance use disorders, specifically alcohol dependence and any drug abuse, and narcissistic and antisocial personality disorders were greater among men with BPD, whereas rates of PTSD were greater among women. By contrast, previous studies found greater rates of paranoid personality disorder among men with BPD, whereas rates in the present study were greater among women. Rates of MDD, dysthymia, panic disorder with agoraphobia, social and specific phobias, and GAD were also greater among women in this study, results not found in clinical studies. Taken together, these results are consistent with suggestions<sup>71,76</sup> that men with BPD manifest impulsivity through externalizing disorders. Alternatively, observed sex differences in the prevalences of Axis I and II disorders may not be associated with the diagnosis of BPD, but, rather, be simply expressions of sex differences in psychopathology. Further prospective research is needed to address the role of BPD in the development of comorbidity among men and women.

Few clinical<sup>77</sup> or epidemiologic<sup>19</sup> studies have examined relationships between race-ethnicity and specific personality disorders. The absence of such data is striking,<sup>77</sup> given that culture is so intertwined with personality, influencing world views, interpersonal relationships, communication styles, coping mechanisms, and self-concept. In contrast to 1 epidemiologic study<sup>19</sup> that found no race-ethnic differences in the imputed rates of BPD and 1 clinical study<sup>77</sup> that found greater rates of BPD among Hispanics, this study found greater rates of BPD among Native American men and lower rates of BPD among Hispanic men and women and Asian women. Why these minorities were found to have differential risk of BPD raises questions regarding the influence of cultural experiences, including acculturation, on personality psychopathology. Whether culturally specific experiences protect against or increase vulnerability to BPD, or whether DSM-IV personality disorder categories are culturally uninformed, are important questions for future clinical and epidemiologic research.

BPD was inversely related to age, with the greatest decline in rates occurring after age 44 years. These findings are consistent with the McLean Study of Adult Development,<sup>78-80</sup> a 10-year longitudinal follow-up of inpatients with BPD. At the time of the 2-year follow-up, 34.5% of patients who were 18 to 35 years old at baseline met criteria for remission; this rate increased to 49.4% at the 4-year follow-up, 68.6% at the 6-year follow-up, and 88.0% at the 10-year follow-up, when the patients were 28 to 45 years old. Consistency of the observed age gradient in the present study with the outcome of the McLean Study suggests that age differences observed in this study are, in part, real and cannot be attributed solely to artifacts such as longer duration of illness, selective mortality, cohort effects, or recall or other biases. Consistent with the clinical literature, it appears that BPD may not be as chronic as

previously recognized. Further prospective epidemiologic research is needed to address this issue more definitively. Determining whether remission of BPD is associated with the development of related, but different, psychopathology also appears warranted in future clinical research.

This study also identified sociodemographic characteristics associated with increased odds of BPD that were not generally reported in previous clinical and epidemiologic research due to limitations in sample size. The rates of BPD were significantly greater among individuals who were separated/divorced/widowed, and among those with low income and education, results that did not vary by sex. Whether being separated/divorced/widowed or of lower socioeconomic status represent true risk factors for BPD, or vice versa, are questions best addressed within a longitudinal framework.

At variance with most<sup>6,81-86</sup> but not all<sup>9</sup> clinical research, this study found that the prevalences of 12-month (59.6%) and lifetime (74.2%) anxiety disorders were similar to those of 12-month (50.9%) and lifetime (75.0%) mood disorders among individuals with BPD. The low to moderate degree of co-occurrence between BPD and anxiety disorders observed in most previous clinical research may reflect the lack of systematic study of a broad range of anxiety disorders. Further research is needed to characterize anxiety disorders more accurately among individuals with BPD, especially given the effectiveness of both pharmacologic<sup>87-94</sup> and cognitive-behavioral<sup>95,96</sup> treatments for many of the most common anxiety disorders. These results also suggest more vigilance in the assessment of anxiety disorders among individuals with BPD.

New findings in this study underscore the importance of controlling for other psychiatric disorders (that are highly comorbid with each other) when examining associations between BPD and other specific disorders.<sup>33,34</sup> Consistent with previous epidemiologic surveys, strong and significant associations were found between BPD and other Axis I and II disorders when sociodemographic characteristics were controlled for. To understand further the unique relationships of other disorders to BPD, we additionally determined the associations controlling for all other disorders assessed in this study. Associations with bipolar I, bipolar II, and narcissistic and schizotypal personality disorders were reduced, but remained strong and significant. The drop in magnitude is analogous to results using twin and genetic study designs and suggests that common causal factors underlie associations between BPD and bipolar disorders and narcissistic and schizotypal personality disorders. However, the remaining associations remained strong after controlling for comorbidity, suggesting that unique factors (e.g., genetic and/or environmental) underlie these disorder-specific associations; for example, the unique factors underlying associations between BPD and bipolar I disorder are not necessarily

the same as those underlying associations between BPD and schizotypal personality disorder.

After control for additional comorbidity, significant but weaker associations remained with alcohol dependence, MDD, social phobia, GAD, and PTSD among men and women. A similar pattern was observed between BPD and drug abuse, nicotine dependence, panic disorder with agoraphobia, specific phobia, and paranoid, histrionic, and avoidant personality disorders among women, and BPD and panic disorder without agoraphobia among men. Thus, while some unique disorder-specific associations were found, much of the association of BPD with these disorders appears due to factors common to these other disorders. Taken together, these findings suggest that unique and common factors may differentially contribute to disorder-specific comorbidity with BPD and that some of these associations appear to be sex-specific. These results highlight the importance of research on common and specific factors underlying the comorbidity of BPD and these disorders. Further, there is a continued need for future research to address sex differences in comorbidity with BPD.

Associations of BPD with alcohol abuse, drug dependence, dysthymia, and schizoid, dependent, and obsessive-compulsive personality disorders were no longer significant among men or women once comorbidity was controlled for. These results strongly suggest that these associations sometimes observed among clinical samples were largely accounted for by other comorbid Axis I and II disorders.

That BPD was associated with a wide range of disability is consistent with the definition of BPD in the DSM-IV as well as with findings from clinical studies.<sup>97,98</sup> Two epidemiologic surveys<sup>99,100</sup> that also controlled for sociodemographic characteristics, medical conditions (for physical disability measures), and Axis I disorders found greater physical and mental disability among individuals with BPD than among those without BPD. This study also found that disability is greater among women than men with BPD, which might explain why females with BPD predominate in clinical samples. Further longitudinal research that builds upon a growing body of recent research in this area is needed to understand the impact of disability on outcome, course, and comorbidity of BPD.<sup>78,80,101</sup>

Potential study limitations are noted. This study is based on data from the Wave 2 NESARC. We were unable to interview respondents to the Wave 1 interview who were deceased or unable or unwilling to participate. However, the Wave 2 response rate, much higher than in most national surveys to date, combined with statistical adjustments for nonresponse at both the person and household levels on numerous sociodemographic characteristics and the presence of any lifetime Wave 1 Axis I or II disorder, considerably minimized the impact of non-

response bias on study findings. Although we used data from the Wave 2 NESARC, the design of this study was cross-sectional, and associations may be subject to recall bias. However, data from the Wave 2 NESARC follow-up will be used to investigate further the temporal relationships between BPD and first incidence of other psychiatric disorders to confirm the observed associations.

In summary, the prevalence of BPD in the general population is greater than previously estimated from epidemiologic surveys. BPD was equally prevalent among men and women and associated with substantial mental and physical disability, especially among women. This study has also identified population subgroups at risk for BPD that have rarely been reported in previous studies. Importantly, BPD was inversely related to age, suggesting that the disorder may be less chronic than previously recognized. This study has also highlighted the need for future epidemiologic, clinical, and genetically informed studies to identify unique and common factors underlying disorder-specific comorbidity with BPD found in the NESARC sample. Important sex differences in rates of and associations with BPD can inform more focused, hypothesis-driven investigations of those factors.

## REFERENCES

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
2. McGlashan TH, Grilo CM, Skodol AE, et al. The Collaborative Longitudinal Study: baseline Axis I/II and II/II diagnostic co-occurrence. *Acta Psychiatr Scand* 2000;102:256–264
3. Paris J. Borderline Personality Disorder. Washington, DC: American Psychiatric Press; 1993
4. Sansone RA. Chronic suicidality and borderline personality. *J Personal Disord* 2004;18:215–225
5. Skodol AE, Gunderson JG, Pfohl B, et al. The borderline diagnosis, I: psychopathology, comorbidity, and personality structure. *Biol Psychiatry* 2002;51:936–950
6. Oldham JM, Skodol AE, Kellman HD, et al. Comorbidity of Axis I and II disorders. *Am J Psychiatry* 1995;152:571–578
7. Skodol AE, Stout RL, McGlashan TH, et al. Co-occurrence of mood and personality disorders: a report from the Collaborative Longitudinal Personality Disorders Study (CLPS). *Depress Anxiety* 1999;10:175–182
8. Trull TJ, Sher KJ, Minks-Brown C, et al. Borderline personality disorder and substance use disorders: a review and integration. *Clin Psychol Rev* 2000;20:235–253
9. Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis I comorbidity of borderline personality disorder. *Am J Psychiatry* 1998 Dec;155(12):1733–1739
10. Zanarini MC, Gunderson JG, Frankenburg FR. Axis I phenomenology of borderline personality disorder. *Compr Psychiatry* 1989;30:149–156
11. Zimmerman M, Mattia JI. Axis I comorbidity and borderline personality disorder. *Compr Psychiatry* 1999;40:245–252
12. Zimmerman M, Rothschild L, Chelminski I. The prevalence of personality disorders in psychiatric outpatients. *Am J Psychiatry* 2005;162:1911–1918
13. Black DW, Noyes R Jr, Pfohl B, et al. Personality disorder in obsessive-compulsive volunteers, well comparison subjects, and their first-degree relatives. *Am J Psychiatry* 1993;150:1226–1232
14. Bodlund O, Ekselius L, Lindström E. Personality traits and disorders among psychiatric outpatients and normal subjects on the basis of the SCID screen questionnaire. *Nord Psykiatr Tidsskr* 1993;47:425–433
15. Coid J, Yang M, Tyrer P, et al. Prevalence and correlates of personality disorder in Great Britain. *Br J Psychiatry* 2006;188:423–431

16. Drake RE, Adler DA, Vaillant GE. Antecedents of personality disorders in a community sample of men. *J Personal Disord* 1988;2:60–68
17. Ekselius L, Tillfors M, Furmark T, et al. Personality disorders in the general population: DSM-IV and ICD-10 defined prevalence as related to sociodemographic profile. *Pers Individ Diff* 2001;30:311–320
18. Klein DN, Riso LP, Donaldson SK, et al. Family study of early-onset dysthymia: mood and personality disorders in relatives of outpatients of dysthymia and episodic major depression and normal controls. *Arch Gen Psychiatry* 1995;52:487–496
19. Lenzenweger MF, Lane MC, Loranger AW, et al. DSM-IV personality disorders in the National Comorbidity Survey Replication. *Biol Psychiatry* 2007 Sep;62(6):553–564
20. Lenzenweger MF, Loranger AW, Korfine L, et al. Detecting personality disorders in a nonclinical population: application of a 2-stage procedure for case identification. *Arch Gen Psychiatry* 1997;54:345–351
21. Maier W, Lichtermann D, Klingler T, et al. Prevalences of personality disorders (DSM-III-R) in the community. *J Personal Disord* 1992;6:187–196
22. Moldin SO, Rice JP, Erlenmeyer-Kimling L, et al. Latent structure of DSM-III-R Axis II psychopathology in a normal sample. *J Abnorm Psychol* 1994;103:259–266
23. Reich J, Yates W, Nduaguba M. Prevalence of DSM-III personality disorders in the community. *Soc Psychiatry Psychiatr Epidemiol* 1989 Jan;24(1):12–16
24. Samuels JF, Nestadt G, Romanoski AJ, et al. DSM-III personality disorders in the community. *Am J Psychiatry* 1994;151:1055–1062
25. Sar V, Akyuz G, Dogan O. Prevalence of dissociative disorders among women in the general population. *Psychiatry Res* 2007;149:169–176
26. Swartz M, Blazer D, George L, et al. Estimating the prevalence of borderline personality disorder in the community. *J Personal Disord* 1990;4:257–272
27. Zimmerman M, Coryell W. DSM-III personality disorder diagnoses in a nonpatient sample: demographic correlates and comorbidity. *Arch Gen Psychiatry* 1989;46:682–689
28. Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. *Arch Gen Psychiatry* 2001;58:590–596
29. Jackson HJ, Burgess PM. Personality disorders in the community: a report from the Australian National Survey of Mental Health and Wellbeing. *Soc Psychiatry Psychiatr Epidemiol* 2000 Dec;35(12):531–588
30. Grant BF, Kaplan KK, Stinson FS. Source and Accuracy Statement for the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Bethesda, Md: National Institute on Alcohol Abuse and Alcoholism; 2005. Available at: <http://www.niaaa.nih.gov>. Accessed Nov 1, 2007
31. Grant BF, Moore TC, Shepard J, et al. Source and Accuracy Statement: Wave 1 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). National Institute on Alcohol Abuse and Alcoholism Web site. Available at: <http://www.niaaa.nih.gov>. Accessed July 2, 2007
32. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry* 2004;61:807–816
33. Compton WM, Thomas YF, Stinson FS, et al. Prevalence, correlates, disability and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry* 2007;64:566–576
34. Hasin DS, Stinson FS, Ogburn E, et al. Prevalence, correlates, disability and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry* 2007;64:830–842
35. Grant BF, Dawson DA, Hasin DS. The Alcohol Use Disorders and Associated Disabilities Interview Schedule—DSM-IV Version. Bethesda, Md: National Institute on Alcohol Abuse and Alcoholism; 2001. Available at: <http://www.niaaa.nih.gov>. Accessed Nov 1, 2007
36. Grant BF, Dawson DA, Hasin DS. The Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions Alcohol Use Disorder and Associated Disabilities Interview Schedule—DSM-IV Version. Bethesda, Md: National Institute on Alcohol Abuse and Alcoholism; 2004. Available at: <http://www.niaaa.nih.gov>. Accessed Nov 1, 2007
37. Compton WM, Conway KP, Stinson FS, et al. Prevalence, correlates, and comorbidity of DSM-IV antisocial personality syndromes and alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry* 2005 Jun;66(6):677–685
38. Grant BF, Hasin DS, Stinson FS, et al. Co-occurrence of 12-month mood and anxiety disorders and personality disorders in the US: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Psychiatr Res* 2005 Jan;39(1):1–9
39. Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, and disability of personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry* 2004 Jul;65(7):948–958
40. First MB, Gibbon M, Spitzer RL, et al. User's Guide for the Structured Clinical Interview for DSM-IV Personality Disorders. Washington, DC: American Psychiatric Press; 1997
41. Loranger AW. International Personality Disorder Examination: DSM-IV and ICD-10 Interviews. Odessa, Fla: Psychological Assessment Resources; 1999
42. Zanarini MC, Frankenburg FR, Sickel AE, et al. The Diagnostic Interview for DSM-IV Personality Disorders. Belmont, Mass: McLean Hospital, Laboratory for the Study of Adult Development; 1996
43. Grant BF, Dawson DA, Stinson FS, et al. The Alcohol Use Disorder and Associated Disabilities Interview Schedule—IV (AUDADIS-IV): reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample. *Drug Alcohol Depend* 2003;71:7–16
44. Ruan WJ, Goldstein RB, Chou SP, et al. The Alcohol Use Disorder and Associated Disabilities Interview Schedule—IV (AUDADIS-IV): reliability of new psychiatric diagnostic modules and risk factors in a general population sample. *Drug Alcohol Depend* 2008 Jan;92(1–3):27–36
45. Zimmerman M. Diagnosing personality disorders: a review of issues and research methods. *Arch Gen Psychiatry* 1994;51:225–245
46. Canino GJ, Bravo M, Ramirez R, et al. The Spanish Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability and concordance with clinical diagnoses in a Hispanic population. *J Stud Alcohol* 1999;60:790–799
47. Chatterji S, Saunders JB, Vrstani R, et al. Reliability of the alcohol and drug modules of the Alcohol Use Disorder and Associated Disabilities Interview Schedule—Alcohol/Drug-Revised (AUDADIS-ADR): an international comparison. *Drug Alcohol Depend* 1997;47:171–185
48. Grant BF, Harford TC, Dawson DA, et al. The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample. *Drug Alcohol Depend* 1995;39:37–44
49. Hasin D, Carpenter KM, McCloud S, et al. The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability of alcohol and drug modules in a clinical sample. *Drug Alcohol Depend* 1997;44:133–141
50. Hasin D, Paykin A. Alcohol dependence and abuse diagnoses: concurrent validity in a nationally representative sample. *Alcohol Clin Exp Res* 1999;23:144–150
51. Hasin DS, Grant B, Endicott J. The natural history of alcohol abuse: implications for definitions of alcohol use disorders. *Am J Psychiatry* 1990;147:1537–1541
52. Hasin DS, Muthén B, Wisnicki KS, et al. Validity of the bi-axial dependence concept: a test in the US general population. *Addiction* 1994 May;89(5):573–579
53. Hasin DS, Van Rossem R, Endicott J. Differentiating DSM-IV alcohol dependence and abuse by course: community heavy drinkers. *J Subst Abuse* 1997;9:127–135
54. Hasin DS, Schuckit MA, Martin CS, et al. The validity of DSM-IV alcohol dependence: what do we know and what do we need to know? *Alcohol Clin Exp Res* 2003;27:244–252
55. Cottler LB, Grant BF, Blaine J, et al. Concordance of DSM-IV alcohol and drug use disorder criteria and diagnoses as measured by AUDADIS-ADR, CIDI and SCAN. *Drug Alcohol Depend* 1997;47:195–205
56. Hasin DS, Grant BF, Cottler L, et al. Nosological comparisons of alcohol and drug diagnoses: a multisite, multi-instrument international study. *Drug Alcohol Depend* 1997;47:217–226
57. Nelson CB, Rehm J, Üstün B, et al. Factor structure of DSM-IV substance use disorder criteria endorsed by alcohol, cannabis, cocaine and opiate users: results from the World Health Organization Reliability and Validity Study. *Addiction* 1999;94:843–855

58. Pull CB, Saunders JB, Mavreas V, et al. Concordance between ICD-10 alcohol and drug use disorder criteria and diagnoses as measured by the AUDADIS-ADR, CIDI and SCAN: results of a cross-national study. *Drug Alcohol Depend* 1997;47:207–216
59. Üstün B, Compton W, Mager D, et al. WHO Study on the reliability and validity of the alcohol and drug use disorder instruments: overview of methods and results. *Drug Alcohol Depend* 1997;47:161–170
60. Vrsti R, Grant BF, Chatterji S, et al. Reliability of the Romanian version of the alcohol module of the WHO Alcohol Use Disorder and Associated Disabilities Interview Schedule–Alcohol/Drug Revised. *Eur Addict Res* 1998;4:144–149
61. Hasin DS, Goodwin RD, Stinson FS, et al. The epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry* 2005;62:1097–1106
62. Grant BF, Hasin DS, Blanco C, et al. The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry* 2005 Nov;66(11):1351–1361
63. Grant BF, Hasin DS, Stinson FS, et al. The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry* 2006 Mar;67(3):363–374
64. Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, comorbidity, and comparative disability of DSM-IV generalized anxiety disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Psychol Med* 2005;35:1747–1759
65. Grant BF, Stinson FS, Hasin DS, et al. Prevalence, correlates, and comorbidity of bipolar I disorder and Axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry* 2005 Oct;66(10):1205–1215
66. Stinson FS, Dawson DA, Chou SP, et al. The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Psychol Med* 2007 Jul;37(7):1047–1059
67. Gandek B, Ware JE Jr, Aaronson NK, et al. Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA Project. International Quality of Life Assessment. *J Clin Epidemiol* 1998 Nov;51(11):1149–1158
68. Research Triangle Institute. Software for Survey Data Analysis (SUDAAN), Version 9.2. Research Triangle Park, NC: Research Triangle Institute; 2006
69. Widiger TA. Invited essay: sex biases in the diagnosis of personality disorders. *J Personal Disord* 1998;12:95–118
70. Morey LC, Alexander GM, Boggs C. Gender. In: Oldham JM, Skodol AE, Bender DS, eds. *Textbook of Personality Disorders*. Washington, DC: American Psychiatric Publishing; 2005:541–549
71. Zlotnick C, Rothschild L, Zimmerman M. The role of gender in the clinical presentation of patients with borderline personality disorder. *J Personal Disord* 2002;16:277–282
72. Skodol AE, Bender DS. Why are women diagnosed borderline more than men? *Psychiatr Q* 2003;74(4):349–360
73. Grilo CM, Anez LM, McGlashan TH. DSM-IV Axis II comorbidity with borderline personality disorder in monolingual Hispanic psychiatric outpatients. *J Nerv Ment Dis* 2002;190:324–330
74. Grilo CM, Sanislow CA, McGlashan TH. Co-occurrence of DSM-IV personality disorders with borderline personality disorder. *J Nerv Ment Dis* 2002;190:552–554
75. Johnson DM, Shea MT, Yen S, et al. Gender differences in borderline personality disorder: findings from the Collaborative Longitudinal Personality Disorders Study. *Compr Psychiatry* 2003;44:284–292
76. Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis II comorbidity of borderline personality disorder. *Compr Psychiatry* 1998;39:296–302
77. Chivara DA, Grilo CM, Shea MT, et al. Ethnicity and four personality disorders. *Compr Psychiatry* 2003;44:483–491
78. Zanarini MC, Frankenburg FR, Hennen J, et al. The McLean Study of Adult Development (MSAD): overview and implications of the first six years of prospective follow-up. *J Personal Disord* 2005;19:505–523
79. Zanarini MC, Frankenburg FR, Hennen J, et al. The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. *Am J Psychiatry* 2003;160:274–283
80. Zanarini MC, Frankenburg FR, Hennen J, et al. Prediction of the 10-year course of borderline personality disorder. *Am J Psychiatry* 2006 May;163(5):827–832
81. Coid JW. An affective syndrome in psychopaths with borderline personality disorder. *Br J Psychiatry* 1993;162:641–650
82. Dahl AA. Some aspects of the DSM-III personality disorders illustrated by a consecutive sample of hospitalized patients. *Acta Psychiatr Scand Suppl* 1986;328:61–67
83. Frances A, Clarkin JF, Gilmore M, et al. Reliability of criteria for borderline personality disorder: a comparison of DSM-III and the Diagnostic Interview for Borderline Patients. *Am J Psychiatry* 1984;141:1080–1084
84. Hudziak JJ, Boffeli TJ, Kriesman JJ, et al. Clinical study of the relation of borderline personality disorder to Briquet's syndrome (hysteria), somatization disorder, antisocial personality disorder, and substance abuse disorders. *Am J Psychiatry* 1996;153:1598–1606
85. Koenigsberg HW, Kaplan RD, Gilmore MM, et al. The relationship between syndrome and personality disorder in DSM-III: experience with 2,462 patients. *Am J Psychiatry* 1985;142:207–212
86. Links PS, Steiner M, Offord DR, et al. Characteristics of borderline personality disorder: a Canadian study. *Can J Psychiatry* 1988;33:336–340
87. Beauclair L, Fontaine R, Annable L, et al. Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentration in plasma and clinical response. *J Clin Psychopharmacol* 1994;14:111–114
88. Griest J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three doses of sertraline and placebo in outpatients with obsessive-compulsive disorder. *Arch Gen Psychiatry* 1995;52:289–295
89. Jefferson JW. Antidepressants in panic disorder. *J Clin Psychiatry* 1997;58(suppl 2):20–24
90. Mancini C, Ameringen MV. Paroxetine in social phobia. *J Clin Psychiatry* 1996 Nov;57(11):519–522
91. Oehrberg S, Christensen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder: a randomized double-blind, placebo-controlled study. *Br J Psychiatry* 1995 Sep;167(3):374–379
92. Rosenbaum JF, Pollack RA. The psychopharmacology of social phobia and comorbid disorders. *Bull Menninger Clin* 1994;58(2 suppl A):A67–A83
93. Tollefson GD, Rampey AH, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. *Arch Gen Psychiatry* 1994;51:559–567
94. Zohar J, Judge R, OCD Paroxetine Study Investigators. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. *Br J Psychiatry* 1996;169:468–474
95. Christensen H, Hadzi-Pavlovic D, Andrews G, et al. Behavior therapy and tricyclic medication in the treatment of obsessive-compulsive disorder. *J Consult Clin Psychol* 1987;55:701–711
96. Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. *Clin Psychol Rev* 1995;15:819–844
97. Skodol AE, Gunderson JG, McGlashan TH, et al. Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder. *Am J Psychiatry* 2002;159:276–283
98. Smith TL, Benjamin LS. The functional impairment associated with personality disorders. *Curr Opin Psychiatry* 2002;15:135–141
99. Cramer V, Torgersen S, Kringle E. Personality disorders and quality of life: a population study. *Compr Psychiatry* 2006;47:178–184
100. Jackson HJ, Burgess PM. Personality disorders in the community: results from the Australian National Survey of Mental Health and Well-being Part III. Relationships between specific type of personality disorder, Axis I mental disorders and physical conditions with disability and health consultations. *Soc Psychiatry Psychiatr Epidemiol* 2004 Oct;39(10):765–776
101. Gunderson JG, Daversa MT, Gilo CM, et al. Predictors of 2-year outcome for patients with borderline personality disorder. *Am J Psychiatry* 2006;163:822–826